Results 271 to 280 of about 6,414,902 (294)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Cancers, 2021
Uwe M Martens, Lionel Larribere, Larribere Lionel   +2 more
exaly  

Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma

Cancers, 2021
M TERESA Cedena, Joaquin Martínez-López, Alberto Orfao   +2 more
exaly  

The Minimal Residual Disease Using Liquid Biopsies in Hematological Malignancies

Cancers, 2022
Joaquin Martínez-López, Rosa María Ayala Diaz, Santiago Barrio   +2 more
exaly  

<p>Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances</p>

Cancer Management and Research, 2020
Francesco Albano, Francesco Albano, Giorgina Specchia   +2 more
exaly  

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients

Journal of Clinical Medicine, 2020
Simona Barbato, Elena Zamagni, Michele Cavo   +2 more
exaly  

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Cancers, 2021
Diana Hanekamp, Peter Valk, Valk Peter J M   +2 more
exaly  

Biomarkers of minimal residual disease and treatment

Minimal residual disease (MRD) has been defined as a very small numbers of cancer cells that remain in the body after curative treatment. Its presence or absence will ultimately determine prognosis. With the introduction of new technologies the presence of MRD in patients with solid tumours can be detected and characterized.
openaire   +2 more sources

Minimal Residual Disease in Multiple Myeloma: Something Old, Something New

Cancers, 2021
CARLOS Bravo-Perez, Andres Jerez, Vicente V   +2 more
exaly  

Determination of minimal residual disease in leukaemia patients

British Journal of Haematology, 2003
Dario Campana
exaly  

Minimal Residual Disease in Lymphoma Revisited

Clinical Lymphoma, 2003
openaire   +2 more sources